search
Back to results

0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy

Primary Purpose

Peripheral Diabetic Neuropathy

Status
Completed
Phase
Phase 3
Locations
Thailand
Study Type
Interventional
Intervention
0.075% Capsaicin Lotion
placebo
Sponsored by
Thammasat University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Diabetic Neuropathy focused on measuring capsaicin, neuropathic pain, diabetic neuropathy, topical lotion

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. DM type 2 over 1 year
  2. Clinical presentation of peripheral sensory such as burning pain
  3. DN4 score from 4 points
  4. Good consciousness to tell their score with informed consent agreement
  5. No adding dosage of previous pain control medications at least 4 weeks
  6. HbA1C 6.5-9.0%

Exclusion Criteria:

  1. Improper application site of skin for topical drugs such as abrasion wound.
  2. Allergic history of Capsaicin
  3. No intention to join the study with any reasons
  4. Other previous medications used that effect to peripheral neuropathy such as Carboplatin, Cisplatin, Colchicine, Dapsone, Etoposide, Ethambutol, Indomethacin, Isoniazid, Lithium, Metronidazole, Phenytoin, Pyridoxine, Statins, Stavudine (d4T) or conditions worsening peripheral nerves following that poor nutrition, kidney failure, chronic alcoholism, vitamin deficiency, Hypothyroidism

Sites / Locations

  • Thammasat University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

0.075% Capsaicin Lotion

Placebo Lotion

Arm Description

0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop

Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop

Outcomes

Primary Outcome Measures

Visual analog scale (0-100 mm.)
scale

Secondary Outcome Measures

Short-form McGill Pain Questionnaire(SF-MPQ)
scale
Neuropathic Pain Scale (NPS)
scale

Full Information

First Posted
April 9, 2017
Last Updated
September 10, 2018
Sponsor
Thammasat University
search

1. Study Identification

Unique Protocol Identification Number
NCT03113448
Brief Title
0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy
Official Title
0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy: A Randomized, Double- Blind, Crossover, Placebo-Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
January 19, 2017 (Actual)
Primary Completion Date
April 21, 2017 (Actual)
Study Completion Date
January 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Thammasat University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To study that 0.075% capsaicin lotion is safe, well tolerated and provide significant pain relief in patients with PDN compared with placebo lotion as a randomized, double- Blind, crossover, placebo-controlled trial
Detailed Description
Neuropathy is one of the most common complications in both type 1 and type 2 diabetes mellitus. The most common symptom is a symmetrical, chronic, axonal, length-dependent sensorimotor polyneuropathy. Topical capsaicin formulations are widely used to manage pain. Low-concentration creams, lotions, and patches intended for daily skin application have been available in most countries since the early 1980s. We study 0.075% capsaicin lotion is safe, well tolerated and provide significant pain relief in patients with PDN compared with placebo lotion as a randomized, double- Blind, crossover, placebo-controlled trial for 20 weeks throughout the study in 42 participants. All participants are provided both 0.075% capsaicin lotion and placebo lotion. Each agent will be applied for 8 weeks then stop for 4 weeks, after that another agent will be used for 8 weeks. We keep following up all of them by calling and appointment to get information in effectiveness and adverse effect at 0,2,4,8,12,14,16,20 week, respectively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Diabetic Neuropathy
Keywords
capsaicin, neuropathic pain, diabetic neuropathy, topical lotion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Model Description
Randomized controlled trial, double blind
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
0.075% Capsaicin Lotion
Arm Type
Active Comparator
Arm Description
0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
Arm Title
Placebo Lotion
Arm Type
Placebo Comparator
Arm Description
Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
Intervention Type
Drug
Intervention Name(s)
0.075% Capsaicin Lotion
Intervention Description
To apply 3-4 times per day, every day until 8 weeks then stop
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
To apply 3-4 times per day, every day until 8 weeks then stop
Primary Outcome Measure Information:
Title
Visual analog scale (0-100 mm.)
Description
scale
Time Frame
20 week
Secondary Outcome Measure Information:
Title
Short-form McGill Pain Questionnaire(SF-MPQ)
Description
scale
Time Frame
20 week
Title
Neuropathic Pain Scale (NPS)
Description
scale
Time Frame
20 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: DM type 2 over 1 year Clinical presentation of peripheral sensory such as burning pain DN4 score from 4 points Good consciousness to tell their score with informed consent agreement No adding dosage of previous pain control medications at least 4 weeks HbA1C 6.5-9.0% Exclusion Criteria: Improper application site of skin for topical drugs such as abrasion wound. Allergic history of Capsaicin No intention to join the study with any reasons Other previous medications used that effect to peripheral neuropathy such as Carboplatin, Cisplatin, Colchicine, Dapsone, Etoposide, Ethambutol, Indomethacin, Isoniazid, Lithium, Metronidazole, Phenytoin, Pyridoxine, Statins, Stavudine (d4T) or conditions worsening peripheral nerves following that poor nutrition, kidney failure, chronic alcoholism, vitamin deficiency, Hypothyroidism
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kongkiat Kulkantrakorn, Professor
Organizational Affiliation
Thammasat University Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Pasiri Sithinamsuwan
Organizational Affiliation
Phramongkutklao College of Medicine
Official's Role
Study Director
Facility Information:
Facility Name
Thammasat University Hospital
City
Pathumthani
ZIP/Postal Code
12120
Country
Thailand

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy

We'll reach out to this number within 24 hrs